BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran CEO, Idan Elmelech COO, Effective April 25; Neil Kumar Appointed Executive Chairman
Benzinga Newsdesk 6 months ago
News
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Pedro J. Beltran, PhD, as Chief Executive
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Pedro J. Beltran, PhD, as Chief Executive Officer and Idan Elmelech as Chief Operating Officer effective April 20th, 2026.